SelectQuote Inc

SelectQuote Inc(SLQT)股票分析

$0.390

-0.080 (-20.61%)收盤時

Loading chart…
最高
0.496
開盤
0.484
成交量加權均價
0.42
成交量
2.03M
市值
463.49M
最低
0.360
成交金額
844.31K
企業價值/稅息折舊攤銷前利潤(TTM)
3.64

SelectQuote, Inc. provides a technology-enabled, direct-to-consumer (DTC) distribution and engagement platform for selling insurance policies and healthcare services. The Company has four core business lines: SelectQuote Senior, SelectQuote Healthcare Services, SelectQuote Life, and SelectQuote Auto and Home. SelectQuote’s Senior division sells Medicare Advantage, Medicare Supplement, Medicare Part D, and other ancillary senior health insurance related products. SelectQuote Healthcare Services comprises SelectRx Pharmacy, a specialized medication management pharmacy, and Population Health which proactively connects its members with healthcare services that fit each member's healthcare needs. SelectQuote’s Auto & Home division primarily sells non-commercial auto and home, property and casualty insurance products. SelectQuote’s Life division sells term life, final expenses, and other ancillary products. SelectRx is a Patient-Centered Pharmacy Home (PCPH) accredited pharmacy.

AI 分析 of SelectQuote Inc (SLQT)

買進

SelectQuote Inc (SLQT) appears to be a good buy right now due to its recent price momentum and favorable valuation metrics. The current price is $0.402, which is significantly below its 52-week high of $2.17, indicating potential for recovery. The stock has shown a 5-day change of +22.90%, reflecting strong short-term performance. Additionally, the forward P/E ratio is 66.67, suggesting that while the stock is expensive based on earnings, it is trading at a low price-to-sales ratio of 0.0395, indicating it may be undervalued relative to its sales. However, the main risk is the negative earnings per share (EPS) estimate of -0.26 for the upcoming quarter, which could lead to further volatility.

估值指標

SelectQuote Inc(SLQT)目前預期本益比為 66.67,5 年平均預期本益比為 2.48。

預期本益比

高估
5 年均值 P/E
2.48
目前P/E
66.67
高估
48.70
低估
-43.74

預期 EV/EBITDA

合理
5 年均值 EV/EBITDA
1.71
目前EV/EBITDA
3.64
高估
54.04
低估
-50.62

預期股價營收比

合理
5 年均值 P/S
0.29
目前P/S
0.06
高估
0.56
低估
0.03

Alphio AI 對 SLQT 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%SLQT

$2.27

情境價格

基

基準

基準 · 50%SLQT

$2.16

情境價格

悲

悲觀

悲觀 · 25%SLQT

$1.66

情境價格

持有 SLQT 的大戶

A

Abrams Bison Investments, L.L.C.

+ 持有SLQT

+8.79%

3個月報酬率

事件時間軸

2026-11-04 (ET)

07:30:00

SelectQuote Reports Q1 Revenue of $280M

07:30:00

Sees FY27 Adjusted EBITDA of $90M-$115M

2026-08-25 (ET)

16:30:00

Major Averages Rise as Chip Stocks Benefit from Nvidia Earnings

12:30:00

Major Averages Slightly Higher, Chip Stocks Benefit from Nvidia Earnings

07:30:00

SelectQuote Q4 Revenue $321.7M, Below Consensus

資訊

SLQT 常見問題 —— 由 Alphio AI 解答

SelectQuote, Inc. provides a technology-enabled, direct-to-consumer (DTC) distribution and engagement platform for selling insurance policies and healthcare services. The Company has four core business lines: SelectQuote Senior, SelectQuote Healthcare Services, SelectQuote Life, and SelectQuote Auto and Home. SelectQuote’s Senior division sells Medicare Advantage, Medicare Supplement, Medicare Part D, and other ancillary senior health insurance related products. SelectQuote Healthcare Services comprises SelectRx Pharmacy, a specialized medication management pharmacy, and Population Health which proactively connects its members with healthcare services that fit each member's healthcare needs. SelectQuote’s Auto & Home division primarily sells non-commercial auto and home, property and casualty insurance products. SelectQuote’s Life division sells term life, final expenses, and other ancillary products. SelectRx is a Patient-Centered Pharmacy Home (PCPH) accredited pharmacy. It operates in the Financials sector (INSURANCE AGENTS, BROKERS & SERVICE industry).

SelectQuote Inc (SLQT) appears to be a good buy right now due to its recent price momentum and favorable valuation metrics. The current price is $0.402, which is significantly below its 52-week high of $2.17, indicating potential for recovery. The stock has shown a 5-day change of +22.90%, reflecting strong short-term performance. Additionally, the forward P/E ratio is 66.67, suggesting that while the stock is expensive based on earnings, it is trading at a low price-to-sales ratio of 0.0395, indicating it may be undervalued relative to its sales. However, the main risk is the negative earnings per share (EPS) estimate of -0.26 for the upcoming quarter, which could lead to further volatility.

暫無貼文

註冊或登入後參與討論

相關文章

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易